BMO Capital Reiterates Outperform Rating on Pfizer (PFE)

September 13, 2024 9:05 AM UTC Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $36.00 price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login